Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Director, Pharmaprojects & Data Integration
UK
+32 year(s) experience
His expertise includes identifying and analyzing trends in pharma R&D. For over 20 years, he has authored the “Pharma Annual R&D review” and its new active substances (NAS) launches supplement. This has become a must-have industry report for those seeking to identify the changing fortunes of drug R&D.
Ian joined Pharmaprojects in 1987, when it was part of PJB Publications. It was acquired by Informa in 2003.
He previously worked in molecular biology as a research assistant at the University of Bristol.Pharmaprojects
By Ian Lloyd 30 May 2019
Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.
Pharmaprojects
By Ian Lloyd 30 May 2019
Pharma R&D Annual Review 2019 is based on the stats and data from from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects.
Topic Clinical trials Diseases Research Drug approval Drug review
Citeline, Scrip, Pharmaprojects
By Ian Lloyd 09 May 2019
April 17, 2019, Pharma R&D Review: What Changed In 2018, What To Look Out For In 2019
Topic Drug approval Research
Pharmaprojects
By Ian Lloyd 12 Mar 2019
Get your head in the game with a free download of the Pharma R&D Annual Review 2019 infographic from Informa Pharma Intelligence. This year’s look at the key players and reigning champs of R&D uses a sports theme to present its critical data on the current state of pharma R&D.
Topic Research Drug development landscape Diseases Drug review
Pharmaprojects
By Ian Lloyd 24 May 2018
Keep in tune with the current landscape for pharma R&D with a free, information-packed webinar recording from Informa Pharma Intelligence. In the Global Pharma R&D Review webinar, our experts hit all the right notes as they used a music theme to explore key issues affecting R&D today, and offer a glimpse of what the rest of 2018 may look like.
Pharmaprojects, Citeline
By Ian Lloyd 15 May 2018
Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.
Topic Research
Pharmaprojects
By Ian Lloyd 10 Apr 2018
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects. Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Pharmaprojects
By Ian Lloyd 22 Mar 2017
Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.
Pharmaprojects
By Ian Lloyd 22 Mar 2017
Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.
Pharmaprojects
By Ian Lloyd 03 May 2016
Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. As such, this list represents a subset of all the first launches which Citeline reported during 2015, excluding the 68 new drug launches with reformulated or non-NAS moieties, or biosimilars.
Pharmaprojects
By Ian Lloyd 01 Feb 2016
For around a quarter of a century now, I've been taking an annual look at the continuing drama which is pharma R&D. Over the past 25 years, we've seen many a twist iand turn in the plot of this particular franchise, and here, we'll look at developments in a year which has seen some new players make the bit time, while others hit skid row after one too many negative (clinical) reviews. We'll see in which companies and diseases we are seeing The Force Awaken, and which are turning out to be merely a Phantom Menace. And we'll industry the types of drugs which are the rising starts and those which are garnering top billing.
Pharmaprojects
By Ian Lloyd 02 Feb 2015
As usual, we start with the keenly-anticipated headline figure, Citeline’s annual count of the total number of drugs in the development pipeline. This year, the news is again stellar:
In Vivo
28 May 2018
Pink Sheet
15 Apr 2016
Pink Sheet
15 Apr 2016
Pink Sheet
14 Apr 2016
Pink Sheet
12 Apr 2016
Pink Sheet
11 Apr 2016
Medtech Insight
11 Apr 2016
Scrip
07 Apr 2016
Pink Sheet
07 Apr 2016
Pink Sheet
05 Apr 2016
Scrip
05 Apr 2016
Pink Sheet
05 Apr 2016
Pink Sheet
04 Apr 2016
Scrip
04 Apr 2016
Scrip
01 Apr 2016
